TP53 and B-cell chronic lymphocytic leukemia: TP53 mutations, which often co-occur with deletion of one allele of chromosome 17p, are associated with clinical resistance to chemotherapy and are the only genetic marker currently used to guide treatment decisions in CLL (50).